CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva ® and Agenerase ® under its 1993 ...

Vertex brought in just over $34 million in royalty revenue from GSK in 2007 for its HIV treatments. The investment entity that purchased the future royalty stream declined to be identified.

Vertex Pharmaceuticals Inc<VRTX.O> said on Tuesday it sold the rights to future royalties on two HIV drugs under a license agreement with GlaxoSmithKline <GSK.L> to unnamed financial ...

Vertex Pharmaceuticals , a small biotech shop, has produced only one drug in 12 years of existence: Agenerase, an also-ran AIDS drug with $80 million in sales (the leader is near $400 million).The ...

Vertex Pharmaceuticals has priced a public offering of 9.1 million shares at $33, hoping to raise slightly more than $300 million in the process. The new terms include an additional 1.1 million ...

Vertex Throws Its Weight At Hep C Jun 05, 2008, 02:05pm EDTJun 19, 2013, 04:50pm EDT ...

[email protected] or Michael Partridge of Vertex Pharmaceuticals, Incorporated, 617-577-6108 [email protected] ...

Biotech firm Vertex Pharmaceuticals Inc. agreed to buy Aurora Biosciences Corp. for about $592 million in stock to gain tools and systems used to search for drug candidates.